Skip to search.

Breaking News Visit Yahoo! News for the latest.

×Close this window

 Dow Down0.12% Nasdaq Down0.07%

Hospira Inc. (HSP)

-NYSE

36.03 Up 0.29(0.81%) May 20, 4:02PM EDT|After Hours : 35.96 Down 0.07 (0.20%) May 20, 4:11PM EDT

Add to Portfolio
ProfileGet Profile for:
Hospira Inc.
275 North Field Drive
Lake Forest, IL 60045
United States - Map
Phone: 224-212-2000
Fax: 302-655-5049
Website: http://www.hospira.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Drug Delivery
Full Time Employees:16,000

Business Summary 

Hospira, Inc. provides injectable drugs and infusion technologies to develop, manufacture, distribute, and markets products worldwide. The company offers specialty injectable pharmaceuticals, which include approximately 200 injectable generic drugs in multiple dosages and formulations; proprietary specialty injectables, including Precedex, a proprietary drug for sedation; and Biosimilars that comprise Retacrit, a biosimilar erythropoietin, which is primarily used in the treatment of anemia in dialysis and in certain oncology applications, as well as Nivestim, a biosimilar filgrastim used for the treatment of low white blood cells in patients who have received a chemotherapeutic agent. It also provides intravenous solutions and nutritional products; and contract manufacturing services. In addition, the company offers medication management products consisting of infusion pumps and dedicated administration sets; Hospira MedNet safety software system and related services; software applications and devices that support point-of-care medication administration; gravity administration sets; and other device products. Further, it is involved in the development of proprietary pharmaceutical products, such as Dyloject, a post-operative pain management drug. The company serves hospitals, clinics, home healthcare providers, and long-term care facilities. It has collaborative arrangements with Bioceuticals Arzneimittel AG to license and market Retacrit; and Q Core Medical, Ltd to market and distribute Sapphire, a multi-therapy infusion system. The company was founded in 2003 and is headquartered in Lake Forest, Illinois.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Hospira Inc.

Corporate Governance 
Hospira Inc.’s ISS Governance QuickScore as of May 1, 2013 is 9. The pillar scores are Audit: 1; Board: 1; Shareholder Rights: 8; Compensation: 9.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Mr. F. Michael Ball , 57
Chief Exec. Officer, Director and Member of Science, Technology & Quality Committee
1.58M0.00
Mr. Thomas E. Werner , 56
Chief Financial Officer and Sr. VP of Fin.
643.00K0.00
Mr. Richard J. Davies , 51
Chief Commercial Officer and Sr. VP
842.00K0.00
Mr. Neil Ryding , 52
Sr. VP of Devices
1.14M0.00
Mr. Matthew R. Stober , 45
Sr. VP of Operations
N/AN/A
Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders